Form 4: Apogee Therapeutics Director Acquires Stock Options

Andrew Gottesdiener, a director at Apogee Therapeutics, acquired stock options for 10,370 shares of common stock on June 5, 2024.

Summary

• Andrew Gottesdiener, a director of Apogee Therapeutics, Inc., filed a Form 4 on June 7, 2024, reporting a transaction that occurred on June 5, 2024.
• The transaction involved the acquisition of stock options for 10,370 shares of Apogee Therapeutics' common stock at an exercise price of $43.85.
• These options vest one year from the grant date, contingent upon Gottesdiener's continued service to the company.
• Gottesdiener is deemed to hold the reported option and the shares underlying the option for the sole benefit of VR Management, LLC, and must exercise the reported option solely upon the direction of the Management Company, which is entitled to the shares underlying the option.
• Gottesdiener disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, and the transaction itself is neither particularly positive nor negative. Sentiment is neutral.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and officers.

Stakeholder Impact

• The acquisition of stock options by a director can be seen as a positive sign by shareholders, indicating confidence in the company's future performance.

Key Dates